Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Central Retinal Vein Occlusion: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Central Retinal Vein Occlusion: 3 US clinical trials tracked, none currently recruiting.
Central Retinal Vein Occlusion is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Long Island Vitreoretinal Consultants, running 1 of these trials.
Enrollment posture brief
Registry condition central-retinal-vein-occlusion
OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Central Retinal Vein Occlusion has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Central Retinal Vein Occlusion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Central Retinal Vein Occlusion is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche
NCT05476926
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Long Island Vitreoretinal Consultants
NCT01231633
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
The Emmes Company
NCT03981549
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Central Retinal Vein Occlusion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Central Retinal Vein Occlusion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Central Retinal Vein Occlusion page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Central Retinal Vein Occlusion trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Long Island Vitreoretinal Consultants sponsors the most Central Retinal Vein Occlusion trials on record, review their full trial history before evaluating a specific study. See Long Island Vitreoretinal Consultants's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Central Retinal Vein Occlusion condition card totals 3 registered trials; most-linked intervention Sham Therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.